Dronedarone/ranolazine - Gilead Sciences
Alternative Names: Ranolazine/dronedaroneLatest Information Update: 16 Mar 2017
At a glance
- Originator Gilead Sciences
- Class Acetanilides; Anti-ischaemics; Benzofurans; Class III antiarrhythmics; Ischaemic heart disorder therapies; Piperazines; Small molecules
- Mechanism of Action Partial fatty acid oxidation inhibitors; Potassium channel antagonists; Pyruvate dehydrogenase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Paroxysmal atrial fibrillation
Most Recent Events
- 16 Mar 2017 Discontinued - Phase-II for Paroxysmal atrial fibrillation in USA, United Kingdom, Poland, Netherlands, Italy, Israel, and Germany (PO), because dronedarone/ranolazine was not listed on Gilead pipeline of March 2017
- 10 May 2014 Final efficacy data from the phase II HARMONY trial in Paroxysmal atrial fibrillation released by Gilead Sciences
- 31 Mar 2014 Gilead Sciences completes the phase II HARMONY trial in Paroxysmal atrial fibrillation in USA, Germany, Israel, Italy, Netherlands, Poland and United Kingdom (NCT01522651)